Published online before print February 14, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
1Correspondence: Dermatology Branch, Center for Cancer Research, National Cancer Institute, Bldg. 10/Rm. 12N238, 10 Center Dr., Bethesda, MD 20892. E-mail: hwangs{at}mail.nih.gov
It is clear from large clinical studies that selected chemokine receptors are often up-regulated in a large number of common human cancers, including those of the breast, lung, prostate, colon, and melanoma. Chemokine receptors and their corresponding chemokine ligands have been demonstrated to play a number of nonredundant roles in cancer metastasis to vital organs as well as regional lymph nodes, the most frequent site of cancer metastasis. Chemokine receptors may potentially facilitate tumor dissemination at several key steps of metastasis, including adherence of tumor cells to endothelium, extravasation from blood vessels, metastatic colonization, angiogenesis, proliferation, and protection from the host response via activation of key survival pathways such as phosphatidylinositol-3 kinase and Akt. It is interesting that many of these roles are reminiscent of their functions in leukocyte and stem cell trafficking. Lastly, we discuss therapeutic applications for chemokine receptor antagonists in cancer therapy.
Key Words: PI-3K • Akt • carcinoma • melanoma
This article has been cited by other articles:
 |
|
 |
|
  V. Levina, B. M. Nolen, A. M. Marrangoni, P. Cheng, J. R. Marks, M. J. Szczepanski, M. E. Szajnik, E. Gorelik, and A. E. Lokshin Role of Eotaxin-1 Signaling in Ovarian Cancer Clin. Cancer Res., April 15, 2009; 15(8): 2647 - 2656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamamoto, H. Kikuchi, M. Ohta, T. Kawabata, Y. Hiramatsu, K. Kondo, M. Baba, K. Kamiya, T. Tanaka, M. Kitagawa, et al. TSU68 Prevents Liver Metastasis of Colon Cancer Xenografts by Modulating the Premetastatic Niche Cancer Res., December 1, 2008; 68(23): 9754 - 9762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Blum, T. Koyama, A. E. M'Koma, J. M. Iturregui, M. Martinez-Ferrer, C. Uwamariya, J. A. Smith Jr., P. E. Clark, and N. A. Bhowmick Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy Clin. Cancer Res., December 1, 2008; 14(23): 7790 - 7797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sung, S. Jhurani, K. S. Ahn, Y. Mastuo, T. Yi, S. Guha, M. Liu, and B. B. Aggarwal Zerumbone Down-regulates Chemokine Receptor CXCR4 Expression Leading to Inhibition of CXCL12-Induced Invasion of Breast and Pancreatic Tumor Cells Cancer Res., November 1, 2008; 68(21): 8938 - 8944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Fang, V. C. Lee, E. Cha, H. Zhang, and S. T. Hwang CCR7 regulates B16 murine melanoma cell tumorigenesis in skin J. Leukoc. Biol., October 1, 2008; 84(4): 965 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Balestrieri, A. Balestrieri, F. P. Mancini, and C. Napoli Understanding the immunoangiostatic CXC chemokine network Cardiovasc Res, May 1, 2008; 78(2): 250 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Amersi, A. M. Terando, Y. Goto, R. A. Scolyer, J. F. Thompson, A. N. Tran, M. B. Faries, D. L. Morton, and D. S.B. Hoon Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine Clin. Cancer Res., February 1, 2008; 14(3): 638 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Redondo-Munoz, M. Jose Terol, J. A. Garcia-Marco, and A. Garcia-Pardo Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration Blood, January 1, 2008; 111(1): 383 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bhandari, J. Trejo, J. L. Benovic, and A. Marchese Arrestin-2 Interacts with the Ubiquitin-Protein Isopeptide Ligase Atrophin-interacting Protein 4 and Mediates Endosomal Sorting of the Chemokine Receptor CXCR4 J. Biol. Chem., December 21, 2007; 282(51): 36971 - 36979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ribaux, J. A. Ehses, N. Lin-Marq, F. Carrozzino, M. Boni-Schnetzler, E. Hammar, J.-C. Irminger, M. Y. Donath, and P. A. Halban Induction of CXCL1 by Extracellular Matrix and Autocrine Enhancement by Interleukin-1 in Rat Pancreatic {beta}-Cells Endocrinology, November 1, 2007; 148(11): 5582 - 5590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Xu, J. Sui, H. Tao, Q. Zhu, and W. A. Marasco Human Anti-CXCR4 Antibodies Undergo VH Replacement, Exhibit Functional V-Region Sulfation, and Define CXCR4 Antigenic Heterogeneity J. Immunol., August 15, 2007; 179(4): 2408 - 2418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Masztalerz, I. S. Zeelenberg, Y. M. Wijnands, R. de Bruijn, A. M. Drager, H. Janssen, and E. Roos Synaptotagmin 3 deficiency in T cells impairs recycling of the chemokine receptor CXCR4 and thereby inhibits CXCL12 chemokine-induced migration J. Cell Sci., January 15, 2007; 120(2): 219 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Becker, M. C. Mihm, S. M. Hewitt, V. K. Sondak, J. W. Fountain, and M. Thurin Markers and Tissue Resources for Melanoma: Meeting Report. Cancer Res., November 15, 2006; 66(22): 10652 - 10657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-h. Lee, T. Kakinuma, J. Wang, H. Zhang, D. C. Palmer, N. P. Restifo, and S. T. Hwang Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol. Cancer Ther., October 1, 2006; 5(10): 2592 - 2599. [Abstract] [Full Text] [PDF]
|
|
